EXPERIMENTAL STUDY

Binding of heparin to human thyroglobulin (Tg) involves multiple binding sites including a region corresponding to a binding site of rat Tg

Simonetta Lisi, Aldo Pinchera, Robert T McCluskey, Luca Chiovato and Michele Marinò

Department of Endocrinology, University of Pisa, Via Paradisa 2, 56124 Pisa, Italy, 1 Pathology Research Laboratory, Massachusetts General Hospital, Harvard Medical School, 149 13th Street, Charlestown, Massachusetts 02129, USA and 2 University of Pavia, Fondazione Salvatore Maugeri, IRCCS, Pavia, Italy

(Correspondence should be addressed to Michele Marinò; Email: m.marino@endoc.med.unipi.it)

Abstract

Objective: Binding of thyroglobulin (Tg) to heparin allows efficient Tg interaction with its endocytic receptor, megalin. Rat Tg (rTg) binds to heparin using an exposed carboxyl terminal region (RELPSRLKRPLVK, Arg2489-Lys2503) rich in positively charged residues which is, however, not entirely conserved in human Tg (hTg) (Arg2489-Glu2503, REPP ARALKRSLWVE). Here, we investigated whether and how this difference affects binding of heparin.

Design: To compare binding of heparin to rTg and hTg. To investigate the role of the sequence 2489–2503 using a peptide-based approach.

Methods: Binding of biotin-labeled heparin to rTg, hTg and to Tg peptides was measured in solid phase assays.

Results: Heparin bound to rTg with moderately high affinity (K_d: 34.2 nmol/l, K_i: 37.6 nmol/l) and to hTg with lower affinity (K_d: 118 nmol/l, K_i: 480 nmol/l) and to a lower extent. Binding was dose-dependent and saturable, and was reduced by several specific competitors (Tg itself, unlabeled heparin, lactoferrin). Heparin bound to synthetic peptides corresponding to the rat (rTgP) and to the human (hTgP) Tg sequence 2489–2503. Heparin bound to rTgP to a greater extent and with greater affinity than to hTgP. An antibody against hTgP reduced binding of heparin to intact hTg by 30%, suggesting that in hTg this region is, in part, involved in heparin binding, but also that other regions account for most of the binding. Starting from the sequence of rTgP, we designed 6 synthetic ‘mutant’ peptides by replacing one amino acid residue of rTgP with the corresponding residue of the sequence of hTgP. Heparin bound to 5 of 6 mutant peptides to a lower extent and with lower affinity than to rTgP.

Conclusions: In spite of a reduced binding ability of the sequence 2489–2503, hTg binds to heparin, in part, using alternative, as yet unidentified, binding sites. Substitution of both positive and neutral residues within the sequence 2489–2503 reduced heparin-binding, suggesting that not only charge, but also sequence and/or conformation, may account for the heparin-binding ability of this region of Tg.

Introduction

Binding of proteins to heparin and to heparin-like molecules, namely glycosaminoglycans (GAGs) occurs mainly through the interaction of negatively charged regions of GAGs with positively charged regions of proteins (1–4). The majority of heparin-binding proteins bind to heparin via short sequences rich in positively charged amino acid residues (arginine and lysine), known as Cardin and Weintraub’s heparin-binding consensus motifs (1–4). However, certain heparin-binding proteins do not contain in their sequence any Cardin and Weintraub’s motifs (1–4). In these cases, binding to heparin occurs via clusters of positively charged amino acid residues that are distant in the sequence and are brought together by the folding of the protein (1–4).

The heparin-binding ability of proteins allows their interaction with GAGs. GAGs, which comprise heparan sulfate proteoglycans (HSPGs), chondroitin sulfates and hyaluronic acid, are among the major components of the extracellular matrix and are attached to the surface of most vertebrate cells (2–4). GAGs are involved in several important biological processes, including cell–cell and cell–matrix interactions, cell proliferation and growth. In addition, GAGs, especially HSPGs, facilitate receptor-mediated endocytosis of certain proteins that bind to cell surface HSPGs (2–4). This interaction
occurs via side-by-side binding sites for the receptor and for heparin (2–4).

Recently, we have studied extensively the endocytic pathway of thyroglobulin (Tg), the precursor of thyroid hormones (5–9). Tg is synthesized by thyroid epithelial cells (thyrocytes) and released into the lumen of thyroid follicles (10–13). Hormone secretion mainly occurs following fluid phase Tg uptake by thyrocytes from the colloid and proteolytic cleavage along the lysosomal pathway (10–13). In addition, Tg can be taken up by receptor-mediated endocytosis, in this case resulting in its recycling into the colloid or in its transepithelial transport (transcytosis) across thyrocytes (10–13).

We found that megalin, a member of the low density lipoprotein receptor family (14–18) present on the apical surface of thyrocytes (19, 20), is responsible for Tg transcytosis (7, 8, 10), a process involved in the regulation of hormone release.

Several lines of evidence led us to the conclusion that efficient binding of rat Tg to megalin requires Tg binding to HSPGs, which occurs via functionally related binding sites for megalin and for heparin (6, 9). First, we found that rat Tg is a heparin-binding protein and that heparin inhibits its binding to megalin, both in solid phase assays (21) and in cultured thyroid cells (5). Secondly, we obtained evidence that the major heparin and megalin binding sites of rat Tg reside in its carboxyl terminal portion (6). Thirdly, we identified a major heparin-binding site of rat Tg and found that occupation of this binding site results in impaired Tg interactions with megalin (6). Fourthly, we obtained evidence that rat Tg binds to HSPGs in vitro and in cultured thyroid cells using the same heparin-binding site needed for megalin binding (9).

As mentioned above, the heparin-binding site of rat Tg which we identified is located in the carboxyl terminal portion of the recently obtained complete sequence of rat Tg (22). To identify this binding site, we used a 15 amino acid synthetic peptide (RELPSRLKRPPLPVK) corresponding to the rat Tg sequence Arg2489-Lys2503, characterized by the presence of a Cardin and Weintraub’s heparin-binding consensus motif (SRLKRP) (6). A rabbit antibody developed against the rat Tg sequence Arg2489-Lys2503 precipitated native, intact Tg, indicating that the sequence is exposed on the surface of the Tg molecule in its native conformation (6). In addition, this antibody markedly reduced (by 70%) binding of heparin to Tg, indicating that this sequence is required for heparin-binding (6).

The heparin-binding sequence we identified in rat Tg is entirely conserved in mouse Tg (23). However, by analysis of the sequence of human Tg (24), we found that the heparin-binding sequence of rat Tg is not entirely conserved (Arg2489-Glu2503, REPPEARALKR-SLWVE). In the present study, we investigated whether and how the different sequences of Tg in rodents and humans affect their heparin-binding ability. The results indicate that, in spite of a markedly reduced heparin-binding affinity of the carboxyl terminal heparin-binding site, human Tg does bind to heparin using, in part, alternative, as yet unidentified, heparin-binding sites. We also found that the heparin-binding affinity of the carboxyl terminal binding site of Tg may depend not only on charge, but also on sequence and/or conformation of the region.

Materials and methods

Materials

Human and rat Tg were prepared by tissue extraction, ammonium sulfate precipitation and column fractionation, as previously described (5–9). The source of human Tg was the contralateral, normal thyroid lobe of a patient subjected to total thyroidectomy for papillary thyroid carcinoma. Written consent was obtained from this patient. Rat Tg (rTg) was obtained from frozen rat thyroids (Pel-Freeze Biologicals, Rogers, AK, USA).

A biotin-labeled heparin–albumin complex, biotin-labeled albumin, unlabeled heparin, lactoferrin, and ovalbumin (OVA) were obtained from Sigma (St Louis, MO, USA). Alkaline phosphatase (ALP)-conjugated streptavidin was obtained from Vector (Burlingame, CA, USA).

Nine 15-mer peptides were synthesized by the Peptide-Protein Core Facility of the Massachusetts General Hospital (Charlestown, MA, USA). The sequences of these peptides and their position within the amino acid sequence of Tg are shown in Table 1. The peptides were designated as reported in Table 1.

An immunoaffinity purified polyclonal rabbit antibody against one of the synthetic peptides (rTgP), raised by Cocalico (Reamston, PA, USA), was previously described and characterized (6). ALP-conjugated goat anti-human IgG was purchased from Sigma.

Selection of human sera containing autoantibodies against a human Tg peptide (hTgP)

Sera from eleven patients (one male and ten females, age range 11–67 years) with autoimmune thyroiditis seen at the Department of Endocrinology of the University of Pisa were collected and numbered from 1 to 11. Written consent was obtained from all patients. All patients had undergone a complete clinical and laboratory thyroid evaluation, which included physical examination, thyroid ultrasonography and the following tests: free thyroid hormones (thyroxine (FT₄) and tri-iodothyronine (FT₃)) RIA, Lysophase, Technogenetics SpA, Milan, Italy), thyrotropic hormone (Ultradsensitive-TSH IFMA, Delfia, Wallac, Finland), anti-Tg autoantibodies (anti-Tg MELISA, Byk Gulden SpA, Milan, Italy) and antithyroidperoxidase autoantibodies (anti-TPO RIA, Sorin...
Biomedica SpA, Saluggia, Italy). The diagnosis of autoimmune thyroiditis was based on the presence of hypothyroidism and circulating anti-Tg and/or antithyperoxidase autoantibodies, with a hypechogenic pattern of the thyroid at ultrasound examination (25). In particular, anti-Tg autoantibodies were detected at high levels in 10 of 11 patients.

The presence of serum IgGs reactive with hTgP was assessed by enzyme-linked immunoadsorbent assay (ELISA). For this purpose, 96-well microtiter plates were coated overnight at 4°C with hTgP (1 mg/ml) in phosphate buffered saline (PBS), in a 100 μl volume. Wells were then blocked for 3 h at 4°C with 1 mg/ml bovine serum albumin (BSA) and washed three times with PBS, 0.05% Tween-20. They were incubated for 3 h at room temperature with sera diluted 1:5 in PBS, containing the anti-hTgP antibody. The beads were previously found to be devoid of anti-Tg autoantibodies. Beads were extensively washed with PBS and then incubated overnight at 4°C with rat Tg, human Tg or the synthetic peptides at various concentrations in PBS, or, as a control, with OV A. For coating, proteins were coated overnight at 4°C with 0.1 – 1000 ng biotin-labeled heparin (0.1 mol/l concentration, after overnight pre-incubation at 4°C. Plates were then washed and incubated with ALP-conjugated anti-human IgG (1:4000) followed by p-nitrophenyl-phosphate (Sigma). Absorbance was determined at 405 nm.

### Table 1 Synthetic peptides used in heparin-binding experiments.

<table>
<thead>
<tr>
<th>Peptide name</th>
<th>Amino acid sequence</th>
<th>Amino acid position in the sequence of Tg</th>
</tr>
</thead>
<tbody>
<tr>
<td>rTgP</td>
<td>REPLSSARLKRPLPVK</td>
<td>Arg2489-Lys2503</td>
</tr>
<tr>
<td>hTgP</td>
<td>REPLPSARLKRPLPVK</td>
<td>Arg2489-Glu2503</td>
</tr>
<tr>
<td>Mutant 5</td>
<td>REPLPSARLKRPLPVK</td>
<td>—</td>
</tr>
<tr>
<td>Mutant 6</td>
<td>REPLPSARLKRPLPVK</td>
<td>—</td>
</tr>
<tr>
<td>Mutant 7</td>
<td>REPLPSARLKRPLPVK</td>
<td>—</td>
</tr>
<tr>
<td>Mutant 8</td>
<td>REPSARLKRPLPVK</td>
<td>—</td>
</tr>
<tr>
<td>Mutant 9</td>
<td>REPSARLKRPLPVK</td>
<td>—</td>
</tr>
<tr>
<td>Control peptide</td>
<td>RELPSGGLGGLPVPY</td>
<td>—</td>
</tr>
</tbody>
</table>

The residues in bold and underlined are those altered with respect to rTgP.

### Purification and characterization of human IgGs reactive against hTgP

Cyanogen bromide activated agarose beads (Sigma) were coupled at saturation with hTgP according to the manufacturer’s instructions. Beads were blocked by incubation for 2 h at 4°C followed by 1 h at room temperature with 10 ml serum from a normal subject previously found to be devoid of anti-Tg autoantibodies. Beads were extensively washed with PBS and then incubated overnight at 4°C with 4.5 ml of a pool of three sera (numbers 6, 7 and 10) from patients with autoimmune thyroiditis that were found to contain autoantibodies against hTgP. Beads were extensively washed with PBS, and IgGs that had been captured by the hTgP-conjugated beads were dissociated from the beads by incubation for a few seconds with 3 ml 0.1 mol/l citric acid, pH 3.3. The beads were spun for a few seconds, the supernatant was collected and buffered by rapidly adding 600 μl Tris (2 mol/l, pH 8.0) to a final pH value of 7.5. The supernatant containing the anti-hTgP antibody was then dialyzed overnight at 4°C against 2 l PBS.

The reactivity of anti-hTgP antibody to hTgP and intact human Tg was tested by ELISA. For this purpose, 96-well microtiter plates were coated overnight at 4°C with hTgP or with intact human Tg or, as controls, with a control peptide (Table 1) or with BSA, all at a concentration of 1 mg/ml in PBS. Wells were blocked with BSA as described above, washed three times with PBS, 0.05% Tween-20, and incubated for 3 h at room temperature with the anti-hTgP antibody diluted 1:10 in PBS, 0.05% Tween-20, 0.5% BSA. Plates were then washed and incubated with the ALP-conjugated anti-human IgG antibody (1:4000), followed by p-nitrophenyl-phosphate. Absorbance was determined at 405 nm.

### Solid phase heparin-binding assays

Solid phase binding assays were performed as described previously (5, 6). Briefly, 96-well microtiter plates were coated overnight at 4°C with rat Tg, human Tg or the synthetic peptides at various concentrations in PBS, or, as a control, with OV A. For coating, proteins were added in a volume of 100 μl/well. After coating, wells were blocked with BSA, washed three times with Tris-buffered saline (TBS) containing 0.05% Tween-20 and incubated for 3 h at room temperature with biotin-labeled heparin (0.1 μg/ml) in TBS, 0.05% Tween-20, 0.5% BSA or, as a control, with biotin-labeled albumin (in which case OVA instead of BSA was used for blocking and in the binding buffer), followed by ALP-conjugated streptavidin (1:3000) and p-nitrophenyl-phosphate (Sigma). Absorbance was determined at 405 nm. The amount of bound heparin or bound albumin was calculated using a standard curve obtained by coating the wells with 0.1–1000 ng biotin-labeled heparin or biotin-labeled albumin.

For inhibition experiments, biotin-labeled heparin was added to the wells alone or together with unlabeled heparin (250 nmol/l), unlabeled rat or human Tg
(various concentrations), lactoferrin (100 μg/ml), anti-rTgP (various concentrations), anti-hTgP (various concentrations) or, as controls, with OVA (various concentrations), normal rabbit IgG (various concentrations) or normal human IgG (various concentrations). In the case of unlabeled rat or human Tg, lactoferrin and OVA, biotin-labeled heparin was also pre-incubated overnight at 4 °C with the competitors.

Results

Binding of heparin to rat and human Tg

Binding of heparin to purified human and rat Tg was studied in solid-phase binding assays, by measuring binding of a biotin-labeled heparin–albumin complex to microtiter wells coated with the two Tg preparations. As shown in Fig. 1A, biotin-labeled heparin bound to both rat and human Tg in a dose-dependent, saturable manner. In contrast, biotin-labeled albumin, used as a control, did not bind to either rat or human Tg (Fig. 1B). Binding of heparin to rat Tg was seen starting at 1.5 nmol/l coated protein, the lowest amount used, whereas binding to human Tg was seen starting at 7.5 nmol/l (Fig. 1A). The extent of binding of biotin-labeled heparin was greater for rat Tg than for human Tg at all the Tg concentrations used for coating. On average, the extent of binding of biotin-labeled heparin to rat Tg was approximately twofold greater than binding to human Tg.

We estimated the constants of dissociation (K_d) and the B_max of binding of biotin-labeled heparin to rat and human Tg at the mid-saturation points (Table 2). Biotin-labeled heparin bound with a greater affinity to rat Tg (mean K_d: 34.2 nmol/l) than to human Tg (mean K_d: 118 nmol/l). As expected from the greater heparin-binding capacity of rat Tg, the B_max was greater for rat Tg (306 pg) than for human Tg (241 pg). However, the higher (~1.2-fold) B_max (binding capacity) of rat Tg did not parallel its greater (~3.4-fold) binding affinity as compared with human Tg.

We studied the effect of pre-incubation and co-incubation of biotin-labeled heparin with increasing concentrations of homologous Tg on its binding to the two Tg preparations at coating concentrations at which saturation of binding was seen (deduced from the experiments shown in Fig. 1), which were 15 nmol/l for rat Tg and 75 nmol/l for human Tg. Binding of biotin-labeled heparin to both rat (Fig. 2A) and human (Fig. 2B) Tg was inhibited in a dose-dependent, saturable manner by rat and human Tg themselves respectively, but not by OVA (used as a control). The extent of inhibition was much greater for rat Tg (~80% at saturation) than for human Tg (~25% at saturation), as expected by the lower binding affinity of human Tg. Thus, the mean constant of inhibition (K_i), was 12-fold lower (37.6 nmol/l, Fig. 2A) for rat Tg than for human Tg (480 nmol/l, Fig. 2B).

As shown in Fig. 3, binding of biotin-labeled heparin to the Tg preparations at coating concentrations at which saturation of binding was seen was reduced by pre-incubation and/or co-incubation of biotin-labeled heparin with several competitors, but not by OVA, used as a control. The extent of inhibition obtained was always greater for rat Tg than for human Tg. Thus, unlabeled heparin reduced binding of biotin-labeled heparin by ~60% to rat Tg and by ~20% to human Tg. Lactoferrin, a potent heparin-binding protein, reduced binding of biotin-labeled heparin to rat Tg by ~45% and to human Tg by ~35%. The results confirm the greater binding affinity of heparin for rat Tg than for human Tg.

![Figure 1](A) Binding of biotin-labeled heparin to rat and human Tg. Wells coated with rat Tg (shaded bars) or human Tg (open bars) or, as a control, with OVA (all zero) were incubated with biotin-labeled heparin, followed by ALP-conjugated streptavidin and p-nitrophenyl-phosphate. Absorbance was determined at 405 nm. Results are expressed as means±S.E. obtained in three separate experiments. (B) Absence of binding of biotin-labeled albumin to rat and human Tg. Wells coated with rat Tg (shaded bars) or human Tg (open bars) were incubated with biotin-labeled albumin, followed by ALP-conjugated streptavidin and p-nitrophenyl-phosphate. Absorbance was determined at 405 nm. Results are expressed as means±S.E. obtained in three separate experiments.
Binding of heparin to synthetic peptides

To study if the different carboxyl terminal sequences of rat and human Tg (corresponding to the heparin-binding site of rat Tg we had identified (6)) influence the heparin-binding ability, we used a synthetic peptide-based approach. For this purpose, we used a previously described synthetic peptide designated rTgP and corresponding to the heparin-binding sequence of rat Tg (6). In addition, we used another synthetic peptide with the corresponding sequence of human Tg (hTgP) (Table 1). Binding of biotin-labeled heparin to rTgP- and hTgP-coated plates was studied in solid phase assays as described above.

As shown in Fig. 4, biotin-labeled heparin bound to both rTgP and hTgP. Binding of biotin-labeled heparin to rTgP was seen starting at 1.25 μmol/l coated peptide, the lowest amount used, whereas binding to hTgP was seen starting at 7.5 μmol/l, a behavior similar to that observed for binding of heparin to rat and human Tg, as described above and in Fig. 1.

Table 2 Binding of biotin-labeled heparin to Tg preparations: mean constants of dissociation (K_d) and B_max.

<table>
<thead>
<tr>
<th></th>
<th>K_d (nmol/l)</th>
<th>B_max (pg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat Tg</td>
<td>34.2</td>
<td>306</td>
</tr>
<tr>
<td>Human Tg</td>
<td>118</td>
<td>241</td>
</tr>
</tbody>
</table>

Figure 3 Inhibition of binding of biotin-labeled heparin to rat Tg (shaded bars) or to human Tg (open bars) by unlabeled heparin or lactoferrin. Wells coated with rat or human Tg were incubated with biotin-labeled heparin alone, or together with unlabeled heparin, lactoferrin (after overnight pre-incubation) or, as a control, with OVA (after overnight pre-incubation), followed by ALP-conjugated streptavidin and p-nitrophenyl-phosphate. Absorbance was determined at 405 nm. Results are expressed as mean ± S.E. percentage of binding obtained in three separate experiments.
Biotin-labeled heparin bound to rTgP to a greater extent than to hTgP at all the peptide concentrations used for coating. On average, the extent of binding of biotin-labeled heparin to rTgP was approximately 100-fold greater than binding to hTgP.

We estimated the $K_d$ of binding of biotin-labeled heparin to the two peptides (Table 3). The estimates indicate that biotin-labeled heparin bound with a greater affinity to rTgP (mean $K_d$: 15 μmol/l) than to hTgP (mean $K_d$: 56 μmol/l). Thus, the binding affinity was about threefold greater for rTgP. The apparent greater extent of binding of biotin-labeled heparin to the rTgP (Fig. 4) than to rat Tg (Fig. 1) can be explained by the much greater molar amounts of coated peptide used (1.5–150 μmol/l) than of coated rat Tg (1.5–150 nmol/l).

The results indicate that the human Tg sequence Arg2489–Glu2503 exhibits heparin binding, although to a lower extent and with lower affinity than the corresponding sequence of rat Tg.

**Mutational study**

The sequences of rat and human Tg in the carboxyl terminal heparin-binding site differ by six amino acid residues (Table 1). In an attempt to investigate which of the six residues are responsible for the lower heparin-binding ability of the human Tg sequence, we used 6 synthetic ‘mutant’ peptides (Table 1). Starting from the rat Tg sequence, each mutant peptide was designed by replacing one amino acid residue with the corresponding residue of the human Tg sequence. The peptides were designated mutants 5 to 10 (mutants 1 to 4 had been used in a previous study (6)).

We tested binding of biotin-labeled heparin to wells coated with the 6 mutant peptides in solid phase binding assays, as compared with binding to rTgP and hTgP. As shown in Fig. 5 and in Table 3, biotin-labeled heparin bound to the mutant peptides to a lower extent and with lower affinity than to the rTgP, with the exception of mutant 9. Thus, as shown in Table 3, $K_d$ values of binding of biotin-labeled heparin to mutants 5, 6, 7, 8 and 10 were three- to sixfold higher than the $K_d$ value of binding of biotin-labeled heparin to rTgP. In contrast, biotin-labeled heparin bound to mutant 9 to a similar extent and with similar affinity ($K_d$: 19 μmol/l) as to rTgP. As compared with hTgP, heparin bound to the mutant peptides to an overall similar extent and with similar affinity, with the exception of mutant 9 to which it clearly bound to a greater extent and with greater affinity.

The results suggest that the greater binding capacity of rTgP may depend not only on charge, but also on sequence and/or conformation, because not only substitution of positively charged amino acid residues, as we found here and in our previous study (6), but also substitution of neutral residues, markedly reduced its heparin-binding capacity.

**Purification and characterization of a human polyclonal antibody against hTgP**

In order to prepare an antibody against hTgP we took advantage of the knowledge that hTgP (amino acids (aa) 2489–2503) overlaps an immunogenic epitope of Tg (aa 2495–2511) that is capable of inducing an experimental autoimmune thyroiditis in rats (26, 27). With the aim of purifying serum IgGs directed against hTgP, we first investigated whether anti-Tg autoantibodies in sera from patients with autoimmune thyroiditis are capable of reacting with hTgP. For this purpose, we used sera from eleven patients with autoimmune thyroiditis, ten of which had been found to contain autoantibodies against Tg. We tested the reactivity of IgGs in these sera against hTgP by ELISA. As shown in Fig. 6A, IgGs in 6 of 10 anti-Tg-positive sera clearly reacted with hTgP, whereas IgGs in the remaining four sera with anti-Tg autoantibodies

<table>
<thead>
<tr>
<th>Peptide</th>
<th>$K_d$ (μmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>rTgP</td>
<td>15</td>
</tr>
<tr>
<td>hTgP</td>
<td>56</td>
</tr>
<tr>
<td>Mutant 5</td>
<td>80</td>
</tr>
<tr>
<td>Mutant 6</td>
<td>50</td>
</tr>
<tr>
<td>Mutant 7</td>
<td>92.5</td>
</tr>
<tr>
<td>Mutant 8</td>
<td>75</td>
</tr>
<tr>
<td>Mutant 9</td>
<td>19</td>
</tr>
<tr>
<td>Mutant 10</td>
<td>75</td>
</tr>
</tbody>
</table>

Table 3 Binding of biotin-labeled heparin to synthetic peptides: mean constants of dissociation ($K_d$).

![Figure 4 Binding of biotin-labeled heparin to synthetic peptides. Wells coated with rTgP (shaded bars) or hTgP (open bars) were incubated with biotin-labeled heparin, followed by ALP-conjugated streptavidin and p-nitrophenyl phosphate. Absorbance was determined at 405 nm. Results are expressed as means ± S.E. obtained in three separate experiments.](https://www.eje.org)
as well as in the serum without anti-Tg autoantibodies did not (numbers 2–5). Three of the six positive sera (sera 6, 7 and 10) were used for further experiments because they were available in larger quantities. As shown in Fig. 6B, binding of IgGs to hTgP in sera 6, 7 and 10 was reduced by ~30 to ~60% by pre-incubation and co-incubation of sera with hTgP itself, indicating that binding was specific. No effect on binding of IgGs to hTgP was produced by co-incubation and pre-incubation of sera with a control peptide (Table 1), used as a negative control.

An antibody against hTgP was then immunoaffinity purified from a pool of sera 6, 7 and 10, as detailed in the Materials and methods section. The reactivity of the anti-hTgP antibody against hTgP and intact human Tg was tested by ELISA. As shown in Fig. 7, the antibody reacted with hTgP and to a greater extent with intact human Tg, probably reflecting the existence of conformational epitopes of human Tg that are not entirely conserved in hTgP. No significant reactivity was found against a control peptide or against BSA used as controls.

**Effect of anti-rTgP and anti-hTgP antibodies on heparin binding to Tg**

In a previous study (6) we demonstrated that a rabbit antibody against rTgP markedly reduced binding of heparin to rat Tg, providing evidence that the rat Tg sequence corresponding to rTgP represents a major binding site for heparin. In confirmation of our previous study (6), here we found in solid-phase binding assays that co-incubation of biotin-labeled heparin with the anti-rTgP antibody reduced its binding to intact Tg in a concentration-dependent, saturable manner, reaching 70% inhibition of binding at saturation (Fig. 8A). No effect was produced by normal rabbit IgG used as a control.
We investigated the effect of the anti-hTgP antibody on binding of biotin-labeled heparin to intact human Tg in solid phase binding assays. As shown in Fig. 8B, co-incubation of biotin-labeled heparin with the anti-hTgP antibody reduced its binding to human Tg in a concentration-dependent, saturable manner, with an inhibition of 30% at saturation. The results suggest that the human Tg region corresponding to hTgP represents a heparin-binding site which, however, contributes to total binding of heparin to a lower extent than the corresponding region of rat Tg. Thus, the contribution of other heparin-binding site/s is greater in human Tg than in rat Tg.

Discussion

The present study was undertaken to investigate the heparin-binding ability of human Tg as compared with rat Tg. Our investigations stemmed from the knowledge that the major heparin-binding site of rat Tg Arg2489-Lys2503 (RELPSRRLKRPLPVK), located
in the carboxyl terminal portion of the molecule (22), is not entirely conserved in human Tg (Arg2489-Glu2503, REPP ARALKRSLWVE) (24). In spite of this difference, we found that human Tg is capable of heparin binding, although to a lower extent and with lower affinity than rat Tg, using alternative, as yet unidentified, heparin-binding sites, in addition to the carboxyl terminal heparin-binding site. Results supporting these conclusions can be summarized as follows.

In confirmation of previous studies (6), biotin-labeled heparin bound to rat Tg in solid-phase binding assays with moderately high affinity ($K_d$: 34.2 nmol/l, $K_i$: 37.6 nmol/l). Here we found that biotin-labeled heparin bound to human Tg, but with lower affinity ($K_d$: 118 nmol/l, $K_i$: 480 nmol/l) and to a lower extent than to rat Tg. Binding to both Tg preparations was dose-dependent and saturable, and was reduced by several specific competitors, including homologous Tg itself, unlabeled heparin and lactoferrin, a potent heparin-binding protein. The extent of inhibition was greater for rat Tg than for human Tg, as expected from the greater heparin-binding affinity of rat Tg.

The carboxyl terminal sequence of human Tg Arg2489-Glu2503 was found to be, in part, responsible for heparin binding. Thus, biotin-labeled heparin bound to a synthetic peptide (hTgP) corresponding to this sequence, although to a lower extent and with lower affinity than to a peptide carrying the corresponding sequence of rat Tg (rTgP). Furthermore, a natural polyclonal human autoantibody capable of recognizing intact human Tg as well as hTgP reduced binding of heparin to intact human Tg.

In an attempt to investigate how the differences in the carboxyl terminal heparin-binding sequences of rat and human Tg affect the heparin-binding ability of this region, we performed a mutational study. We designed 6 synthetic ‘mutant’ peptides by replacing one amino acid residue of rTgP with the corresponding residue of the human Tg sequence. Biotin-labeled heparin bound to 5 of the 6 mutant peptides to a lower extent and with lower affinity than to rTgP. Because not only substitution of positively charged amino acid residues, as we found here and in our previous study (6), but also substitution of neutral residues reduced the heparin-binding ability of rTgP, we postulate that not only charge, but also sequence and/or conformation may account for the heparin-binding ability of this region of Tg. Results obtained with mutants 5 and 9 suggest that sequence may be more important than conformation in the case of mutant 9. In both these mutants neutral amino acid residues were substituted with other neutral residues. In mutant 5 substitution of leucine with proline reduced the heparin-binding ability, whereas in mutant 9 substitution of proline with tryptophan had virtually no effect. Because proline is known to be more prone to affect conformation than tryptophan, if the heparin-binding ability were entirely dependent on conformation, a reduced binding would have been expected in mutant 9 where proline was replaced by tryptophan.

Figure 8 Inhibition of binding of biotin-labeled heparin to rat (A) or to human (B) Tg by antibodies directed against a carboxyl terminal heparin-binding site. Wells coated with rat (A) or human (B) Tg were incubated with biotin-labeled heparin alone, or together with various concentrations of rabbit anti-rTgP (A) or of human anti-hTgP (B), or, as controls, with normal rabbit (A, RlgG) or human (B, hlgG) IgG, followed by ALP-conjugated streptavidin and p-nitrophenyl-phosphate. Absorbance was determined at 405 nm. The figures are representative of one of three separate experiments.
Thus, replacement of proline with another neutral amino acid residue (tryptophan) in mutant 9 should have affected conformation as did replacement of leucine with proline in mutant 5. Nevertheless, whether sequence or conformation or both are responsible for heparin binding and how they contribute to the heparin-binding ability of this Tg region is unknown. Further studies are needed to clarify these issues, aimed at investigating whether and how the possibly different conformational modes of the various Tg peptides affect their heparin-binding ability, after their three-dimensional structure is discovered through crystallization studies. In addition, further studies using peptides carrying simultaneously more than one mutation may also be useful in clarifying these issues.

As mentioned above, in a previous study we demonstrated that the carboxyl terminal rat Tg sequence Arg2489-Lys2503 represents a major heparin-binding site (6). In addition, this sequence is required for rat Tg binding to HSPGs (9). The fact that a rabbit antibody raised against Arg2489-Lys2503 (rTgP) reduced heparin-binding to rat Tg by only 70%, led us to the conclusion that other heparin-binding sites must account, in part, for binding (6). However, although by analysis of the rat Tg sequence we identified an alternative potential heparin-binding site in another region of Tg, we failed to demonstrate its involvement in heparin-binding (6). Therefore, we concluded that, most likely, additional heparin-binding sites must correspond to clusters of positively charged amino acids, distant in the sequence, but brought together by the folding of the protein.

Several considerations indicate that the corresponding carboxyl terminal sequence of human Tg Arg2489-Glu2503 contributes only minimally to its overall heparin-binding ability, and that other regions must be involved to a greater extent, in contrast with rat Tg. First, the lower heparin-binding capacity of human Tg did not parallel linearly its lower binding affinity as compared with rat Tg, indicating that human Tg can compensate for a lower heparin-binding affinity with the presence of multiple heparin-binding sites. Secondly, the lower heparin-binding affinity of hTgP compared with rTgP did not parallel linearly the difference between human and rat Tg; it was in fact much lower: 100-fold vs 3.4-fold. This finding indicates that the contribution of the region of human Tg corresponding to hTgP to total heparin-binding must be rather low, unless the conformation of this region in the intact molecule differs from the conformation of hTgP in a way that allows a greater heparin-binding affinity. Thirdly, and more importantly, the anti-hTgP antibody reduced binding of biotin-labeled heparin to intact human Tg by only 30% at saturation whereas, as mentioned above, the corresponding region of rat Tg contributes 70% to heparin-binding.

By analysis of the sequence of human Tg (24), we did not find any putative heparin-binding sites (Cardin and Weintraub’s motifs). Therefore, as in the case of rat Tg, we concluded that other heparin-binding sites must correspond to clusters of positively charged amino acid residues, distant in the sequence but brought together by the folding of the protein. The optimal way to study how conformation affects the heparin-binding ability of a protein is to analyze its three-dimensional structure, to locate regions rich in positively charged residues and to determine whether they are brought together by the folding of the protein. However, this approach is not currently possible in the case of Tg, because its three-dimensional structure is not known. Another way to study putative heparin-binding sites is by site-directed mutagenesis studies (28). However, this approach is unlikely to be feasible in the case of Tg. Thus, although Kim et al. (29) have succeeded in transfecting a nearly full length Tg gene in cultured cells, point mutations in the carboxyl-terminal portion abolished secretion of the protein, thereby making it impossible to obtain preparations of purified mutated Tg.

The heparin-binding ability of proteins allows their interaction with GAGs (2–4). In the case of rat Tg, binding to HSPGs allows optimal binding to its endocytic receptor, megalin (9). Further studies are needed to investigate whether and how the difference in the sequence of human Tg and its different heparin-binding capacity affect its binding to HSPGs. Recently, Siffroi-Fernandez et al. (30) provided evidence that the human Tg carboxyl terminal region from Ser2445 to Met2596, comprising the sequence we studied here (Arg2489-Glu2503), is involved in low affinity Tg binding to as yet unidentified molecules on thyroid cell membranes. Based on the results presented here it is worth considering the possibility that binding may be due to HSPGs.

Tg is thought to be present in the colloid in a variety of folding modes and a relevant proportion of Tg in the colloid is multimerized and insoluble and undergoes partial proteolysis (31–40). Therefore, it is possible that not all the Tg forms present in the colloid display the same behavior concerning heparin binding and endocytosis, and certain forms may bind to HSPGs and to Tg receptors to a greater extent than others. Because, as mentioned above, the three-dimensional structure of Tg is unknown, it is impossible at the moment to study directly how folding of Tg affects its heparin-binding ability. The Tg preparations used in the present study corresponded exclusively to the soluble forms of Tg as, during Tg purification, the insoluble forms are commonly discarded. Therefore, whether our results apply to multimerized Tg or to Tg that has undergone partial proteolysis is unknown and requires further investigation. Nevertheless, results presented here are relevant for understanding the mechanisms of Tg binding to heparinoids in the general context of Tg endocytosis and hormone release. Thus, under physiological conditions the forms of Tg that undergo
hormone release following endocytosis are soluble and have not undergone proteolysis prior of endocytosis, as they are thought to be the first secreted by thyocytes after their synthesis (last come first served theory) (41). In this view, as we have shown in previous studies (7, 9), the Tg that is endocytosed by the receptor megalin – a process facilitated by Tg binding to HSPGs and that is involved in the regulation of hormone release – is soluble, intact and hormonogenic, as were the Tg preparations used in the present study (not shown).

The difference in the heparin-binding ability between human and rat Tg may represent the consequence of an evolutionary adaptation of the thyroid to the necessity of a high metabolic rate in rodents. Binding to HSPGs may render rat Tg uptake and hormone release more efficient than in larger mammals, resulting in a higher metabolic rate. Further studies are needed to investigate these issues.

Acknowledgements
This work was supported by the American Thyroid Association Research grant (to M M), by grants from the National Research Council (Consiglio Nazionale Ricerche, Roma, Italy) (grants 91.01219 and 9300437, to AP and LC), by EEC Stimulation Action-Science Plan (contract SC1-CT91-0707, to AP and LC) and by a grant from the Italian Association for Cancer Research (AIRC, to M M).

References
14 Raychowdhury R, Niles JL, McCluskey RT & Smith JA. Autoimmune target in Heymann nephritis is a glycoprotein with homology to the LDL receptor. Science 1989 244 1163–1165.
24 Malthiery Y & Lisitsky S. Primary structure of human thyroglobulin deduced from the sequence of its 8448-base complemen-
28 Wong P, Hampton B, Seylebrt E, Gallagher AM, Jaye M & Burgess WH. Analysis of putative heparin-binding domains of fibroblast growth factor-1. Using site-directed mutagenesis and peptide ana-

www.eje.org


41 Schneider PB. Thyroidal iodine heterogeneity: 'last come first served' system of iodine turnover. *Endocrinology* 1964 **74** 973–980.

Received 12 September 2001
Accepted 7 January 2002